Novo Nordisk A/S: Diabetes Mellitus, Type 1 trials

The registry lists 226 Diabetes Mellitus, Type 1 studies with Novo Nordisk A/S as lead sponsor. 2 are open to participants now and 32 have results posted.

Phase 1 75Phase 2 8Phase 3 53Phase 4 12No phase 78(a study in two phases counts in both)

Studies

Page 1 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Research Study Investigating the Effect of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and Participants With Type 1 Diabetes With Overweight or ObesityRecruitingNCT07578584Phase 1
• General Use-results Surveillance With Awiqli in Patients With Diabetes MellitusRecruitingNCT06807190
• A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)CompletedNCT04848480Phase 3Results posted
• Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With DiabetesCompletedNCT04588259Phase 3Results posted
• Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 DiabetesCompletedNCT03816761Phase 2Results posted
• Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 DiabetesCompletedNCT03377699Phase 3Results posted
• Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 DiabetesCompletedNCT02825251Phase 3Results posted
• Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 DiabetesCompletedNCT02670915Phase 3Results posted
• Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 DiabetesCompletedNCT02500706Phase 3Results posted
• A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell FunctionCompletedNCT02443155Phase 2Results posted
• The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 DiabetesCompletedNCT02098395Phase 3Results posted
• A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 DiabetesCompletedNCT02034513Phase 3Results posted
• A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 DiabetesCompletedNCT01999322Phase 3Results posted
• The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 DiabetesCompletedNCT01836523Phase 3Results posted
• A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes MellitusCompletedNCT01835431Phase 3Results posted
• Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 DiabetesCompletedNCT01831765Phase 3Results posted
• Investigation of Pain During Subcutaneous Injections With Different Injection Speed and Volume CombinationsCompletedNCT01680328Phase 1Results posted
• A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 DiabetesCompletedNCT01569841Phase 3Results posted
• A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes MellitusCompletedNCT01513473Phase 3Results posted
• Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell TransplantationTerminatedNCT01206101Phase 2Results posted
• Comparison of NN1250 With Insulin Glargine in Type 1 DiabetesCompletedNCT01079234Phase 3Results posted
• Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 DiabetesCompletedNCT01074268Phase 3Results posted
• Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 DiabetesCompletedNCT00982228Phase 3Results posted
• Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 DiabetesCompletedNCT00978627Phase 3Results posted
• Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 DiabetesCompletedNCT00841087Phase 2Results posted
• Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in DiabeticsCompletedNCT00773279Phase 3Results posted
• Observational Study to Evaluate the Safety of Levemir® in DiabetesCompletedNCT00659295Results posted
• Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689CompletedNCT00623194Phase 3Results posted
• Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 DiabetesCompletedNCT00612040Phase 2Results posted
• Comparison of Insulin Detemir and Insulin Aspart in 2 Separate Injections Twice Daily to Extemporaneous Mixing Injection Regimen Twice Daily - The Paediatric Mixing TrialCompletedNCT00542620Phase 4Results posted
• Effect of Insulin Detemir on Use of Energy in Type 1 DiabetesTerminatedNCT00509925Phase 4Results posted
• Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 DiabetesCompletedNCT00474045Phase 3Results posted
• Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 DiabetesCompletedNCT00447382Phase 3Results posted
• Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 DiabetesCompletedNCT00435019Phase 3Results posted
• A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 DiabetesCompletedNCT07305805Phase 1
• A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood SugarActive, not recruitingNCT07160816
• A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 DiabetesActive, not recruitingNCT07087795Phase 1
• A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 DiabetesActive, not recruitingNCT07076199Phase 3
• User Experience With DuraTouch® in Patients With Type 1 or Type 2 DiabetesCompletedNCT07052292
• A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insulin PumpCompletedNCT06809621Phase 1
• A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 DiabetesCompletedNCT06685185Phase 1
• Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese AdolescentsCompletedNCT06588504Phase 1
• Phase 2 Study of INV-202 in Patients With Diabetic Kidney DiseaseCompletedNCT05514548Phase 2
• A Study to Look at How Insulin NNC0471-0119 Works in the Body in People With Type 1 Diabetes When Injected by Insulin PumpCompletedNCT05262595Phase 1
• A Multiple Dose Study Investigating Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Participants With Type 1 Diabetes Pharmacokinetics and Pharmacodynamics: How Insulin NNC0363-0845 is Transported Throughout the Body and How It WorksCompletedNCT05134987Phase 1
• A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical PracticeCompletedNCT05069545
• A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 DiabetesCompletedNCT04698018Phase 1
• A Study to Look at How Safe Insulin NNC0471-0119 is and How it Works in People With Type 1 Diabetes MellitusCompletedNCT04655690Phase 1
• A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 DiabetesCompletedNCT04569994Phase 1
• An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical PracticeCompletedNCT03987802
• A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 DiabetesCompletedNCT03965013Phase 1
• Effect of Fiasp® in Type 1 Diabetes TreatmentCompletedNCT03895515
• A Research Study of How Different Amounts of a New Medicine NNC0148-0287 C (Insulin 287) Works on the Blood Sugar of People Who Are Japanese With Type 1 Diabetes When Given Once a WeekCompletedNCT03766854Phase 1
• A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a WeekCompletedNCT03723772Phase 1
• A Research Study Looking at How Faster Aspart Injected in Double Concentration Works in the Body of People With Type 1 Diabetes MellitusCompletedNCT03723759Phase 1
• A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes MellitusCompletedNCT03674866
• Study on How Fiasp® Can Influence Blood Sugar Levels of type1 Diabetic Patients in Their Daily Lives, With the Help of the Freestyle Libre® DeviceCompletedNCT03450863
• First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.CompletedNCT03444467Phase 1
• A Regulatory Post Marketing Surveillance (rPMS) Study of Ryzodeg® FlexTouch® (Insulin Degludec /Insulin Aspart) to Evaluate Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice in KoreaCompletedNCT03416855
• A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 DiabetesCompletedNCT03407599Phase 1
• Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.CompletedNCT03220425Phase 3
• A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 DiabetesCompletedNCT03215498Phase 1
• A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes MellitusCompletedNCT02938572Phase 1
• Investigating the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes MellitusCompletedNCT02662114
• A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen®CompletedNCT02627287Phase 1
• A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 DiabetesCompletedNCT02612844Phase 1
• Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 DiabetesCompletedNCT02568280Phase 1
• Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes MellitusCompletedNCT02536859Phase 1
• Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes MellitusCompletedNCT02392117
• Changing Diabetes in ChildrenTerminatedNCT02382757
• A Survey on Low Blod Sugar Among Insulin-treated Patients With DiabetesCompletedNCT02306681
• A Survey on Hypoglycaemia Among Insulin-treated Patients With DiabetesCompletedNCT02230631
• Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in IndiaCompletedNCT02230618
• A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes MellitusCompletedNCT02220296Phase 1
• A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 DiabetesCompletedNCT02131246Phase 1
• A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in IndiaCompletedNCT02117622
• A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 DiabetesCompletedNCT02035371Phase 1
• A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 DiabetesCompletedNCT02033239Phase 1
• A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 DiabetesCompletedNCT02003677Phase 1
• A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 DiabetesCompletedNCT01992588Phase 1
• Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®CompletedNCT01984372
• GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes MellitusCompletedNCT01950650
• A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 DiabetesCompletedNCT01934712Phase 1
• A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 DiabetesCompletedNCT01924637Phase 1
• Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year PeriodCompletedNCT01900834
• An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy RegistryCompletedNCT01892319
• Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 DiabetesCompletedNCT01868568Phase 1
• Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes MellitusCompletedNCT01868529Phase 1
• Investigation of Pharmacodynamic Characteristics of Explorative Formulation of Insulin Degludec in Male Subjects With Type 1 DiabetesCompletedNCT01865318Phase 1
• Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With DiabetesCompletedNCT01865305Phase 1
• Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 DiabetesCompletedNCT01865292Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Explorative Formulation of Insulin DegludecCompletedNCT01865279Phase 1
• An Observational Study to Assess Longitudinal Variation of Immune Biomarkers in Subjects at Risk for Development of Type 1 DiabetesCompletedNCT01846312
• A Trial Investigating the Effect of Acute Hypoglycaemia on Cognitive Function and Brain Activation Patterns in Subjects With Type 1 DiabetesCompletedNCT01789593Phase 1
• A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 DiabetesCompletedNCT01773798Phase 1
• A Trial Investigating the Safety, Tolerability, and Distribution and Activity in the Body of NNC0148-0000-0287 Injected Under the Skin in Healthy Subjects and in Subjects With Type 1 DiabetesCompletedNCT01730014Phase 1
• Safety of Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes MellitusCompletedNCT01709929Phase 3
• Safety and Efficacy of Insulin Aspart in Subjects With Type 1 DiabetesCompletedNCT01707134Phase 3
• A Trial Comparing the Effect of Exercise on Blood Glucose in Subjects With Type 1 Diabetes, Who Are Treated With Either Insulin Degludec or Insulin GlargineCompletedNCT01704417Phase 1
• Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir in Well Controlled Subjects With Type 1 DiabetesCompletedNCT01697657Phase 3